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ABSTRACT Integrins are cell surface receptors found on
monocytes that facilitate adhesion to both cellular and extra-
cellular substrates. These Integrins are thought to be involved
in the selective gene induction observed after monocyte adhe-
sion to various extracellular matrices. To investigate this
hypothesis, we stimulated monocytes with monoclonal antibod-
ies to different integrin receptors to specifically mimic the
integrin receptor-ligand interactions. Engagement of the com-
mon .8 chain of the Pli subfamily of integrins resulted in
expression ofthe iammator mediator genes, interleukln 113,
interleukin 1 receptor antagonist, and monocyte adherence-
derived Inflaatory gene 6 (MAD-6), whereas engagement of
the common P chain of the 12 family did not. Furthermore, to
characterize integrin-mediated gene induction, we examined
the ability of antibodies to the a chain of integrin receptors to
regulate gene expression. Engagement of the very late antigen
4 (VLA-4) receptor resulted in induction of all the mediator
genes. Receptor crosslinking was required because individual
Fab faments were unable to stimulate gene induction whereas
the divalent F(ab')2 fragment and the whole IgG molecule
could. Interleukin 11 secretion was dependent on the anti-
integrin antibody used. Some antibodies required a second
signal and, for others, direct engagement was sufficient for
protein production. In conclusion, engagement of integrin
receptors regulated the production of both inflNmmatory me-
diator mRNA and protein. These results suggest that integrin-
dependent recognition and adherence may provide the key
signals for initiation of the inflammatory response during
monocyte diapedesis.
During an inflammatory process, extravasating monocytes
rapidly and transiently adhere to the endothelial cells lining
the arteries and capillaries and to various extracellular and
basement membrane components (1). Cell adhesion is facil-
itated through a family ofcell surface receptors, the integrins.
Integrins are a(8 heterodimeric glycoproteins that are respon-
sible for cell-cell and cell-matrix interactions (2, 3). The
integrin superfamily is comprised of at least eight subfamilies
based on the unique structure of the various 13 chains (2-4).
In addition to serving as a receptor responsible for mediating
cell-cell or extracellular matrix (ECM) contact, integrins also
link the exterior of the cell to the interior of the cell. The
cytoplasmic portion of the integrins is associated with the
actin cytoskeletal framework via the accessory proteins talin,
vinculin, a-actinin, and possibly others (5).
Because adhesion receptors play a paramount role in the
connection of a substrate/ligand to the cytoskeleton, an
additional function of these transmembrane glycoproteins
would be in signal transduction. Several groups have shown
that the adherence ofCD4+ T cells to fibronectin via the very
late antigen (VLA)-4 and VLA-5 integrins (6-8) or to laminin
via the VLA-6 integrin (6) provides a necessary costimulatory
signal that mediates CD3-dependent T-cell proliferation. Ad-
hesion to vascular cell-adhesion molecule 1 (VCAM-1)
through its receptor VLA-4 also provides a costimulatory
signal for CD3-dependent activation of CD4+ T cells (9, 10).
Engagement of the P2 integrin, lymphocyte function-
associated antigen (LFA)-1, with its ligand, intracellular-
adhesion molecule 1 (ICAM-1/CD54) (10, 11), or with mono-
clonal antibodies (mAbs) (12, 13) further demonstrates that
these receptors act as costimulatory molecules in T-cell
activation. CD2, LFA-3(CD58), and CD44 have also been
implicated in mediating T-cell activation (14-16). Cell regu-
lation in non-T cells via adhesion receptors has also been
reported (17-23). Stimulation of the PI1 integrins serves as a
required intermediate for interleukin 1 (IL-1)-induced alka-
line phosphatase activity in osteosarcoma cells (17). Adhe-
sion of suspension-arrested fibroblasts to fibronectin rapidly
induces c-fos and c-myc expression (18), whereas adhesion of
keratinocytes to fibronectin results in cell-cycle withdrawal
and inhibition of terminal differentiation (19). Additional
studies in fibroblasts showed that engagement of the fibro-
nectin receptor (VLA-5) acts as an activator of the Na/H
antiporter (20) and an inducer of the collagenase and stro-
melysin genes (21). In monocytes, LFA-3, CD44, and CD45
engagement can trigger tumor necrosis factor and IL-1 re-
lease (22) and, in carcinoma cells, 81 integrin engagement
stimulates tyrosine phosphorylation (23).
No direct evidence exists for immediate-early gene induc-
tion in monocytes via the VLA integrins, although the above
mentioned work certainly suggests their potential role in
signal transduction and consequent gene induction. For our
work, we concentrated on the 81 and 132 subfamilies. The P1i
subfamily [VLA or CD49(a-f)/CD29 integrins] is primarily
considered to be responsible for the adherence of cells to
ECM components such as collagen, fibronectin, and laminin.
This subfamily is composed of six known members, VLA-1
to VLA-6 (ref. 24). The P2 subfamily [CD11(a-c)/CD18
integrins] is considered to be important primarily in cell-cell
adherence and is composed of three members, LFA-1,
Mac-1, and p150/95 (2, 3).
Adherence results in the induction of the inflammatory
mediator genes IL-113, tumor necrosis factor, and colony-
stimulating factor and the protooncogene c-fos (25-28). Sev-
eral monocyte adherence-derived (MAD) inflammatory
genes are also regulated by adherence (29-31). More impor-
tantly, these early studies showed that monocyte adhesion to
various ECM proteins differentially regulated the levels and
types of genes induced (26, 29). In this study we wanted to
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determine whether the previous results showing that adhe-
sion regulates inflammatory mediator gene expression was
due to specific integrin engagement. To examine this hypoth-
esis, we used mAbs to the ,1 and 12 subfamilies of integrins
to stimulate monocytes nonadherently. In this report, we
show that direct integrin engagement regulated steady-state
mRNA levels and protein secretion.
MATERIALS AND METHODS
Isolation of Monocytes. Briefly, whole blood from random
donors was diluted 1:2 in RPMI 1640 medium and centrifuged
through Ficoll/Histopaque 1077 (Sigma) (32). The buffy coat
cells were collected and washed with sterile isotonic saline to
remove platelets. Monocytes were isolated from the rest of
the buffy coat cells by centrifugation through Percoll (Phar-
macia) (33), washed in sterile saline, counted, and then used
at 10-20 x 106 cells per treatment group. In our hands, this
isolation procedure does not result in monocyte activation
(25). Each experiment used the monocytes isolated from one
random donor.
Culture Conditions. Monocytes were cultured in endotox-
in-free RPMI 1640 medium (GIBCO) at 370C and 5% C02/
95% air on either polystyrene tissue culture dishes (Coming)
or nonadherently in polypropylene tubes (Fisher Scientific)
with constant rocking for 1-4 hr, with or without mAbs
depending on the experiment.
Reagents. The anti-131 ,8-subunit-specific mAb AIIB2 was a
generous gift of Caroline H. Damsky (University of Califor-
nia, San Francisco) (21); the anti-31 13-subunit-specific mAbs
LIA1/2, LIA1/5, TS2/16, and TS2/16 F(ab')2 and the anti-
VLA-4 a-subunit-specific mAbs HP1/7, HP2/1, HP2/4,
HP2/4 Fab, and HP2/4 F(ab')2 were a generous gift of
Francisco Sanchez-Madrid and Miguel R. Campanero (Uni-
versidad Autonoma de Madrid) (34, 35). The anti-132 13-sub-
unit-specific mAb 60.3 was a generous gift of John M. Harlan
(University of Washington) (36) and the anti-,82 13-subunit-
specific mAbs KIM-127 and KIM-185 were a generous gift of
Martyn K. Robinson (Celltech, Watertown, MA) (37). Mono-
cytes were preincubated with the mAbs for 20 min at 40C and
then incubated for 1-4 hr at 370C. When mAbs were added
sequentially, monocytes were first pretreated at 40C with the
first mAb for 20 min, incubated for 15 min at 370C, and then
incubated with the second mAb for 1 hr at 370C. Initial studies
were carried out with saturating levels of mAbs (10 pug/ml).
Subsequent studies used the mAbs at a final concentration of
1 Ag/ml, as stimulation was similar when up to a 1:1000
dilution was used.
RNA Isolation and Northern Blot Analysis. Total RNA was
isolated by the guanidine isothiocyanate/cesium chloride
method (38). mRNA levels were determined by Northern blot
analysis. Total RNA (5 ,ug) was electrophoresed on a 1%
denaturing agarose gel and then transferred to nitrocellulose
(Schleicher & Schuell) (39). Multiple blots were done from
each experiment and all RNA levels were equivalent based
on 18S and 28S rRNA levels (data not shown); however, all
the data presented are from multiple probes of the same blot.
Nitrocellulose blots were probed with 32P-labeled cDNA
probes made using a random-priming kit (Boehringer Mann-
heim). Hybridizations were incubated overnight in a 50%o
(vol/vol) dimethylformamide solution at 420C. Blots were
washed to a final stringency of 0.2x SSPE (1x SSPE = 0.18
M NaCl/10mM phosphate, pH 7.4/1 mM EDTA) at 560C and
then exposed to Kodak XAR2 x-ray film (Eastman Kodak)
with intensifier screens at -70'C.
Protein Quantification. Secreted IL-113 was determined by
incubating isolated nonadhered monocytes for 4 hr with or
without lipopolysaccharide (LPS; 10 ng/ml). Duplicate sam-
ples of supernatant from each treatment group were col-
lected, centrifuged, and frozen at -20°C. IL-113 in culture
supernatants was quantitated by a capture ELISA kit (Cis-
tron, Pine Brook, NJ). All values represent the average ofthe
protein secretion in pg/ml from duplicate samples. In exper-
iments with polymyxin (10 ng/ml; Roerig Div./Pfizer), the
polymyxin was added prior to monocyte incubation.
RESULTS
I31Integin but Not P2 Integrin Engagement Regulates Gene
Induction. We have been interested in examining gene ex-
pression in monocytes adhering to different surfaces as a
model for understanding the mechanisms involved in mono-
cyte regulation ofthe inflammatory process during diapedesis
(25, 26). To examine this process, we used mAbs to the
common 13 chain of the P( (mAb TS2/16) and P2 (mAb 60.3)
integrins to specifically and directly mimic receptor-ligand
interactions (Fig. 1). Engagement of the f1 integrins resulted
in induction of IL-1f3, IL-1 receptor antagonist (IL-ira), and
MAD-6 mRNA (lane 3), whereas engagement of the 132
integrins did not induce gene expression (lane 4). Crosslink-
ing of the primary anti-/32 mAb with a secondary mAb also
failed to induce a signal (data not shown). Because the lack
of gene induction via engagement of 132 integrins could be a
result of negative signaling or simply a lack of a signal, we
examined whether preincubation of monocytes with the
anti-832 mAb could block 813-mediated receptor signaling.
From Fig. 1, lane 6, it can be seen that prior 132 engagement
affects mRNA levels differently depending on the gene
examined; no significant decrease in IL-1,8 expression and a
modest suppression of MAD-6 expression were observed.
The reverse treatment group, prior,81 engagement (lane 5),
showed no differences in IL-1,8 or MAD-6 but an enhance-
ment of IL-ira expression.
To further examine 813-mediated signaling, a panel of
anti-,31 integrin mAbs was used. AIIB2 induced high levels of








FIG. 1. Pt but not /2 integrin engagement with mAbs regulates
immediate-early gene induction. Northern blot analysis of human
monocytes treated with mAb (anti-Pi, TS2/16; anti-,82, 60.3). Lane
TO' contains monocytes harvested immediately after isolation and
lane NAD contains monocytes incubated for 1 hr without mAb.
mAbs were used at a final concentration of 1 ,ug/ml and monocytes
were incubated nonadherently for 1 hr. RNA levels were equivalent
based on 18S and 28S rRNA levels. All data are from a single donor
and are from a representative experiment that was repeated at least
three times.
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but other mAbs, TS2/16 and LIA1/5, were less active (lanes
4 and 5, respectively). Stimulation was not the result of Fc
binding, as the TS2/16 F(ab')2 preparation was highly stim-
ulatory (lane 6).
Because mAbs TS2/16 and 60.3 were not of the same
isotype (IgGi and IgG2a, respectively), additional P2 mAbs
were examined (Fig. 3). Other anti-.82 mAbs did not signal
mRNA expression (lanes 5 and 6). The two mAbs KIM are
IgGi, thus eliminating isotype differences (37). Interestingly,
KIM-127 was recently shown by Robinson et al. (37) to
promote LFA-1 and complement receptor-3-dependent
events in human B- and T-cell lines (37). Additional anti-132
and anti-CD11a and -CDilb mAbs also could not stimulate
gene induction in monocytes (A.D.Y., unpublished data).
VLA-4 Receptor a-Chain Engagement Results In Inflam-
matory Gene Induction. We next investigated whether
changes in mRNA levels could be elicited by direct engage-
ment of the integrin a subunits. Monocytes were stimulated
nonadherently with a panel ofmAbs specific for the a subunit
of VLA-4 (a43j). VLA-4 is a receptor for the ECM compo-
nent, fibronectin, and the activated endothelial marker
VCAM-1 (24, 40) and has recently been shown to be a
mediator of leukocyte homotypic aggregation (35, 41, 42).
Although the anti-VLA-4 a-chain-specific mAbs HP1/7,
HP2/1, and HP2/4 recognize different VLA-4 epitopes (35,
42), each induced IL-1if, IL-ira, and MAD-6 mRNA (Fig. 4).
Higher levels of gene induction were observed with the two
cell-aggregation-inducing mAbs, HP1/7 and HP2/4 (lanes 3
and 5, respectively), as compared to the nonaggregating mAb
HP2/1 (lane 4). Monocytes adhered to plastic (lane 1) were
used as a positive control (25, 26, 29). Engagement of the
VLA-4 fibronectin receptor resulted in the unexpected acti-
vation of the collagen-specific gene MAD-6 (29). Isotype
differences can be ruled out as the anti-VLA-4 mAbs were all
the same isotype (IgGl). With some donors, a low induction
ofMAD-6 in the control (lane 2) was seen. This result may be
due to MAD-6 being selectively induced at low levels by rapid
but transient cell-cell interactions.
Divalent Receptor Crosslinking Is Necessary for mRNA
Expression. Although crosslinking of the primary antibody
with a secondary antibody is not necessary for the transmis-
sion of signal in monocytes, divalent crosslinking of the
receptors may be necessary. Therefore, HP2/4 Fab and
F(ab')2 fragments and the whole molecule were examined for
their ability to mediate steady-state mRNA levels (Fig. 5).
Crosslinking of receptors appears to be required for gene
induction since binding of individual Fab fragments (lane 4)
did not stimulate a response when compared to intact whole
antibody, F(ab')2 fragments, or the positive plastic-adhered
control (lanes 3, 5, and 6, respectively). Because the F(ab')2
fragments stimulated gene induction, Fc receptor interac-
tions as a source for gene induction can be discounted. In
fact, increased levels of IL-1i, IL-ira, and MAD-6 expres-
r j
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FIG. 3. Additional anti-12 mAbs do not induce gene expression
in human monocytes. Northern blot analysis of human monocytes
after stimulation by mAbs. TS2/16 is an anti-pi mAb and 60.3, KIM
127, and KIM 185 are anti-P2 mAbs. Other details are as in Fig. 1
except that the experiment was repeated twice.
sion occurred with the use of the F(ab')2 fragments, suggest-
ing a potential negative signaling event may occur through the
Fc receptor.
IL-1p Protein Secretion Is Regulated by Direct Inegrin
Engagement. Adherence to plastic served as a priming signal
for monocytes but a second signal was needed to trigger
protein production (25). In the present study, we treated
nonadhered monocytes identically to those collected for
mRNA expression except that monocytes were incubated for
4 hr in LPS-free medium or with low levels ofLPS (10 ng/ml).
From Table 1, it can be seen that two of the anti-(31 mAbs,
TS2/16 and LIA1/5, could directly stimulate IL-1,B secretion
without an additional secondary signal. The other mAbs,
LIA1/2 and HP1/7, needed a second signal provided by LPS
for monocyte protein secretion. Anti-P2 mAb 60.3 did not
stimulate protein secretion. Because the direct effect of
TS2/16 and LIA1/5 on protein production could be the result
of LPS contamination in the antibody fractions, polymyxin
(10 ,ug/ml) was added to all samples. The addition of poly-
myxin completely inhibited IL-1,B secretion in the sample
groups requiring LPS as a second signal but not in the groups
that did not need a second signal. This data demonstrates that
integrin-mediated signaling can directly regulate protein pro-
duction (primes and triggers) and that such signaling appears
to be antibody-dependent since only specific antibodies elic-





FIG. 2. A Northern blot analysis of human monocytes IL-1,
induction after stimulation by a panel of mAbs demonstrating that
variations exist in integrin-mediated signaling. LIA1/2, LIA1/5, and
TS2/16 are anti-,B1 mAbs. Other details are as in Fig. 1.
FIG. 4. VLA-4 receptor engagement regulates monocytes gene
induction. Northern blot analysis of monocyte integrin engagement
after stimulation with VLA-4 a chain mAbs (HP1/7, HP2/1, HP2/4).
Other details are as in Fig. 1.
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FIG. 5. Monomeric Fab fragments do not stimulate immediate-
early gene induction, showing that divalent crosslinking of integrins
is needed. HP2/4 whole molecule and F(ab')2 and Fab fragments
were used at a final concentration of 1 ,ug/ml. Other details are as in
Fig. 1 except that the experiment was repeated at least twice.
DISCUSSION
The adherence of extravasating monocytes to endothelial
cells lining the capillaries and to extracellular and basement
membrane components is the first step in the path of a
circulating monocyte to a site of inflammation. We have
shown (25, 26, 29) that this initial adherence step modulated
monocyte expression of key inflammatory mediator genes,
suggesting that adherence serves as a primary regulatory
stimulus. Further studies showed that adherence of mono-
cytes to different ECM components selectively regulated
gene induction (26, 29). Because integrins selectively regulate
adhesion to different substrates and have been implicated by
others to be potential signal transduction molecules in other
cell types (6-13, 17-21, 23), we investigated their potential
role in specific monocyte adherence-mediated signaling and
consequent gene induction.
By using direct receptor engagement as a model, we
showed that engagement of (31 but not P2 integrins induced
mRNA expression. Differences in gene expression were not
due to mAb isotype differences but rather appear to be due
to the lack of signaling (leading to mRNA expression).
Furthermore, preliminary studies with soluble ICAM-1 also
showed no gene induction (A.D.Y., unpublished data). This
lack ofa signal generated by the anti-182 mAbs does not appear
to be due to differences in the rate mAbs are internalized, as
cells labeled with anti-pi1 and anti-P32 mAbs and then incu-
bated showed similar fluorescent surface patterns.
Studies with T cells showing that the (2 integrin LFA-1 acts
as a costimulatory molecule were done with immobilized
anti-LFA-1 (12) or ICAM-1 (10, 11) or crosslinked anti-
LFA-1 (13), suggesting (32 receptor crosslinking and perhaps
events regulated by adherence itself or some other costimu-
latory signal are necessary for a response. Furthermore,
these studies showed that (32 engagement only provided a
costimulatory signal and that a second signal was needed.
Diamond et al. (43) showed that LFA-1 and Mac-1 bind to
different domains of ICAM-1 and suggest that each could
provide a unique signal (43). This latter possibility seems
likely, because while investigating whether P2 integrins may
send a negative signal rather than no signal, we showed that
preincubation of cells with anti-(32 prior to anti-(31 modestly
down-regulated MAD-6 expression but not IL-1i( expression.
Table 1. IL-1,8 secretion by mAb-stimulated monocytes
IL-1p secreted, pg/ml
mAb 1 2 3A 3B 3C 3D
NAD 9.2 L L L L 99.6
TS2/16 101.6 155.2 102.4 31.7 29.8 351.2
LIA1/2 18.8 L L L L 886.1
LIA1/5 288.7 188.8 184.8 50.8 84.7 711.0
HP1/7 25.2 L L L 8.3 320.7
60.3 14.4 L L L L 94.0
TS2/16, LIA1/2, LIA1/5 are anti-81 mAbs; HP1/7 is an anti-
VLA-4 mAb; and 60.3 is an anti-X32 mAb. In experiments 1, 2, and 3A,
monocytes were stimulated without LPS. Experiments 1, 2, and 3A
are identical experiments with different donors. Values represent
averages from duplicate samples measured by ELISA. In experiment
3B, monocytes were treated as experiment 3A except that polymixin
(10 ng/ml) was added. Experiment 3C is the same as 3A except that
polymixin (10 ng/ml) plus LPS (10 ng/ml) were added. Experiment
3D is the same as 3A except that LPS (10 ng/ml) was added. L
indicates a value below the limit of detection.
The differential effects of prior (2 compared with prior (3
engagement could be the result of differences in aggregation;
however, additional studies showed that there were no dif-
ferences in the number of monocytes aggregated after incu-
bation with either anti-P( or anti-f32 mAbs (A.D.Y., unpub-
lished data). These data suggest that (32 engagement in
monocytes may specifically transmit a signal, but the signal
transmitted does not directly induce mRNA and may need a
costimulatory signal to mediate a full response.
To further clarify the mechanisms involved in receptor
signaling, mAbs to the a chain of the VLA-4 receptor were
used to triggermRNA expression. The VLA-4 receptor is one
of the three 381 fibronectin receptors (24). It recognizes the
CS-1 segment of fibronectin, independent of the RGD amino
acid sequence, the recognition site for VLA-5 (44). VLA-4 is
atypical because it also recognizes the endothelial cell marker
VCAM-1 and may be directly responsible for leukocyte
homotypic aggregation (24, 35, 40-42). Gene expression was
induced by engagement of the VLA-4 receptor. The impor-
tance of the VLA-4 receptor and signaling through it comes
from studies of patients with P2 adhesion deficiencies (leu-
kocyte adhesion deficiency) in which neutrophils fail to move
to sites of inflammation, whereas monocytes and lympho-
cytes move normally (3, 45). VLA-4 is present on monocytes
and lymphocytes but not neutrophils and may be the key
adherence receptor for monocyte and lymphocyte trafficking
(46).
In monocytes, signaling through the VLA integrins re-
quires only divalent crosslinking and not the addition of
secondary antibody to crosslink. This has also been observed
in keratinocyte differentiation (19) and in studies examining
collagenase and stromelysin expression in fibroblasts, after
stimulation with anti-fibronectin receptor antibodies (21).
This lack of necessity for secondary crosslinking of integrins
is in contrast to T-cell (6-16) and other systems (23), where
immobilization or secondary crosslinking and/or costimula-
tion is necessary for signaling.
MAD-6 is a collagen- but not fibronectin-selective gene
described by Sporn et al. (29) and is equivalent to the A-20
zinc finger apparent transcription factor (which inhibits pro-
grammed cell death) (50). Engagement of the VLA-4 receptor
unexpectedly induced MAD-6 mRNA. One possible expla-
nation for this may be that integrin engagement with the
biological ligand fibronectin results in a unique set of signals
that are different from those generated by the anti-VLA-4
antibodies. This possible explanation is supported by a study
(21) that observed that different signals were generated
depending on whether the natural fibronectin ligand, fibro-
nectin fragments, or antibodies to the fibronectin receptor
Immunology: Yurochko et al.
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were used. Alternatively, because VLA-4 binds VCAM-1,
we could be mimicking the VCAM-1-VLA-4 interactions
with the anti-VLA-4 mAbs. Our previous observation that
monocytes adhered to an endothelial cell line express MAD-6
(29) raises the possibility that VCAM-1-VLA-4 interactions
induce the putative transcription factor MAD-6.
Finally in the present study, we addressed protein secre-
tion stimulated by integrin engagement. Adherence has been
shown to prime monocytes and a second signal was needed
to induce protein production (25). In this work, we demon-
strated that two anti-p3i mAbs directly stimulate IL-1pB secre-
tion without an additional secondary signal. Adherence to
plastic may result in different signaling pathways than those
seen after (, integrin engagement [preliminary phosphoryla-
tion studies support that conclusion (A.D.Y., unpublished
data)]. The differences between the responses generated after
treatment with various antibodies may be due to differences
in the affinity of binding of the individual antibodies. Alter-
natively, it could be due to differences in signaling based on
the unique epitopes recognized by the various mAbs. This
suggestion that different epitopes regulate different re-
sponses is supported by the work of Pulido et al. (42) who
described different functional epitopes on at least the VLA-4
integrin. The anti-832 mAb did not stimulate protein secretion,
supporting the conclusion that P82 engagement does not
provide the necessary signals for mRNA expression or pro-
tein secretion. These data also provide additional evidence
that LPS was not contaminating our monocytes or mAb
stocks, because many of the mAbs without exogenously
added LPS could not stimulate protein secretion but did elicit
IL-1,8 transcripts.
Thus these results clearly demonstrate that direct integrin
engagement in monocytes regulates both steady-state mRNA
and protein levels. From our present data, one could envision
that, as an extravasating monocyte adheres to the cells lining
the capillaries and then to the ECM through the P1 integrins,
inflammatory mediator genes and products would be in-
duced, resulting in a local and perhaps systemic response.
The importance of fully understanding this pathway is clear,
especially in cases of chronic inflammatory diseases where
increased amounts of fibronectin or collagen can be found
(47, 48). Increased amounts of matrix components could
cause hyper or aberrant signaling through adhesion recep-
tors, resulting in an unregulated or an uncontrolled inflam-
matory response. These results emphasize the central role of
the common ,81 chain in regulating inflammatory responses
(49).
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